Johnson & Johnson (JNJ)

259.01
-5.73 (-2.16%)
NYSE · Last Trade: Oct 1st, 1:53 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close264.74
Open263.68
Bid258.94
Ask259.01
Day's Range258.72 - 263.98
52 Week Range181.07 - 281.07
Volume2,949,652
Market Cap680.87B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield5.360 (2.07%)
1 Month Average Volume6,382,812

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

These dow jones stocks are moving in today's sessionchartmill.com
Via Chartmill · October 1, 2026
Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continuemarketbeat.com
Jabil posted a double-beat quarter with nearly 29% revenue growth and 34% EPS growth, driven by AI demand, while maintaining buybacks and a Buy-rated analyst consensus.
Via MarketBeat · October 1, 2026
History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade.fool.com
Medtronic is following a strategy that has worked well for Johnson & Johnson.
Via The Motley Fool · October 1, 2026
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Johnson & Johnson (NYSE: JNJ) today released new findings that show most women know menopause can affect mood and sleep, but fewer than half realize their eye health may change too. A new global survey of 6,000 women found that only 40% connect eye changes with the menopause transition—even though 90% say seeing clearly and comfortably helps them feel confident, capable or like themselves.i
By Johnson & Johnson · Via Business Wire · October 1, 2026
Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.fool.com
Analysts think this beaten-down healthcare stock will rebound.
Via The Motley Fool · October 1, 2026
If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's Thisfool.com
New investors might be eager to jump in during a bull market.
Via The Motley Fool · October 1, 2026
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record Highfool.com
This is not an exhaustive list.
Via The Motley Fool · September 30, 2026
3 Healthcare Dividend Stocks Offering More Than Just Incomemarketbeat.com
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
Via MarketBeat · September 30, 2026
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does.fool.com
SHCD is missing some of the healthiest dividend stocks.
Via The Motley Fool · September 30, 2026
Which dow jones stocks are moving on Tuesday?chartmill.com
Via Chartmill · September 29, 2026
Uncover the latest developments among dow jones stocks in today's session.chartmill.com
Via Chartmill · September 29, 2026
Top dow jones movers in Monday's sessionchartmill.com
Via Chartmill · September 28, 2026
Uncover the latest developments among dow jones stocks in today's session.chartmill.com
Via Chartmill · September 28, 2026
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?fool.com
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
Via The Motley Fool · September 25, 2026
Friday's session: top gainers and losers in the dow jones indexchartmill.com
Via Chartmill · September 25, 2026
Stay informed with the top movers within the dow jones index on Thursday.chartmill.com
Via Chartmill · September 24, 2026
Thursday's session: top gainers and losers in the dow jones indexchartmill.com
Via Chartmill · September 24, 2026
Bear Markets May Feel Frightening, But Here's How You Can Come Out Aheadfool.com
The next bear market may be your best opportunity to grow your portfolio.
Via The Motley Fool · September 24, 2026
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?fool.com
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
Via The Motley Fool · September 24, 2026
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?fool.com
Wall Street thinks that this robotic surgical systems leader's sell-off is overdone.
Via The Motley Fool · September 24, 2026
2 Stocks to Buy Hand Over Fist if a Stock Market Crash Is Comingfool.com
You can take these companies' dividends straight to the bank.
Via The Motley Fool · September 23, 2026
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
DePuy Synthes, a global leader in orthopaedic technologies and solutions, will showcase its latest trauma innovations at the 2026 Orthopaedic Trauma Association (OTA) Annual Meeting in Nashville, including four new VOLT™ plating systems, MAXFRAME AUTOSTRUT™ with Bluetooth® Multi-Axial Correction System, VELYS™ Trauma AI Assisted Surgery enabling technology, and an expanded value offering for procedural solutions.
By DePuy Synthes · Via Business Wire · September 22, 2026
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signalfool.com
Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.
Via The Motley Fool · September 21, 2026
The Investing Playbook for Retirees Who Can't Afford to Losefool.com
It may not be possible to avoid all risks, but it's certainly possible to minimize them.
Via The Motley Fool · September 21, 2026
Meet the Vanguard ETF That Increased Its SpaceX Holding by 39% in 1 Month and Shows No Signs of Slowing Downfool.com
The unlocking of SpaceX shares is reshaping the communications sector.
Via The Motley Fool · September 20, 2026